Showing results (341-350 of 414) with videos related to
Sort By:
Pageof 42
Cell|November 15, 1996
The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivoQ Wang, T Stacy, J D Miller, et al.Nature|May 3, 2023
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistanceJoon Seok Park, Francesca S Gazzaniga, Meng Wu, et al.Nature Immunology|August 12, 2025
A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunityMartin W LaFleur, Lauren E Milling, Priyamvada Prathima, et al.Cell|June 26, 2018
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint BlockadeWanqiang Sheng, Martin W LaFleur, Thao H Nguyen, et al.The Journal of Experimental Medicine|February 27, 2024
Framework for in vivo T cell screensLauren E Milling, Samuel C Markson, Qin Tjokrosurjo, et al.Proceedings of the National Academy of Sciences of the United States of America|August 4, 2019
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockadeMohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, et al.Nature|August 9, 2016
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapySe Jin Im, Masao Hashimoto, Michael Y Gerner, et al.Cell Reports|May 3, 2018
Role of Selenof as a Gatekeeper of Secreted Disulfide-Rich GlycoproteinsSun Hee Yim, Robert A Everley, Frank A Schildberg, et al.Cancer Immunology Research|June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockadeZachary A Cooper, Vikram R Juneja, Peter T Sage, et al.Immunity|June 26, 2012
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1Kiyoshi Hirahara, Kamran Ghoreschi, Xiang-Ping Yang, et al.Pageof 42